Home › Triple-Negative Breast Cancer › Minnesota › Minneapolis
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Minneapolis, MN
Isang pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Minneapolis. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
PRE-ISPY Phase I/II Oncology Platform Program
Nagre-recruitPhase 1/2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Nagre-recruitPhase 3
- Allina Health Cancer Institute ( Site 0069), Minneapolis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Nagre-recruitPhase 3
- Metro-Minnesota Community Clinical Oncology ( Site 0031), Saint Louis Park · 5 mi ang layo
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Nagre-recruitPhase 3
- Virginia Piper Cancer Center (Allina Health), Minneapolis
- University of Minnesota Medical Center, Fairview, Minneapolis
- Metro Minnesota Community Oncology, Saint Louis Park · 5 mi ang layo
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, Minneapolis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Nagre-recruitPhase 2/3
- Local Institution - 0372, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Nagre-recruitPhase 2
- University of Minnesota, Minneapolis
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park · 5 mi ang layo
Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod
- Houston, TX42 pag-aaral
- New York City, NY31 pag-aaral
- Nashville, TN28 pag-aaral
- Los Angeles, CA27 pag-aaral
- Boston, MA26 pag-aaral
- San Antonio, TX23 pag-aaral
- St. Louis, MO21 pag-aaral
- Arlington, VA20 pag-aaral
- Atlanta, GA20 pag-aaral
- Dallas, TX18 pag-aaral
- Chicago, IL16 pag-aaral
- Columbus, OH16 pag-aaral
Iba pang pag-aaral sa Minneapolis
- Non-Small Cell Lung Cancer27 pag-aaral
- Kanser sa Suso27 pag-aaral
- Kanser sa Ovary24 pag-aaral
- Kanser sa Prostate23 pag-aaral
- Kanser (lahat ng uri)22 pag-aaral
- Pagkabigo ng Puso21 pag-aaral
- Acute Myeloid Leukemia20 pag-aaral
- Kanser sa Baga20 pag-aaral
- Colorectal Cancer19 pag-aaral
- Kanser ng Endometrium18 pag-aaral
- Sakit ni Parkinson17 pag-aaral
- Sakit sa Puso at Ugat ng Dugo15 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.